Journal Home > Volume 2 , Issue 1
Cancer Innovation 2023, 2(1): 1-17 https://doi.org/10.1002/cai2.46
Review | Open Access | Issue | Published: 21 February 2023

Advances in medical treatment of breast cancer in 2022

Show Author's Information Jingtong Zhai1,  Yun Wu1,  Fei Ma1 ( ),  Virginia Kaklamani2 ( ),  Binghe Xu1( )
Department of Medical Oncology, National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
Division of Hematology, Oncology, UT Health San Antonio MD Anderson Cancer Center, San Antonio, Texas, USA

Jingtong Zhai and Yun Wu contributed equally to this work and shared the first authorship.

Keywords:
nonsmall cell lung cancer, small cell lung cancer, perioperative period, late stage, new immunotherapy
Cite this article:
Zhai J, Wu Y, Ma F, et al. Advances in medical treatment of breast cancer in 2022. Cancer Innovation, 2023, 2(1): 1-17. https://doi.org/10.1002/cai2.46
Download citation
EndNote(RIS)
BibTeX

945

Views

72

Downloads

Citations

3

Crossref

N/A

WoS

2

Scopus

N/A

CSCD

Abstract Full text About this article

Lung cancer is the malignant tumor with the highest morbidity and mortality in China, and nonsmall cell lung cancer is a common form of lung cancer. After undergoing chemotherapy and molecular targeted therapy, the treatment of lung cancer has now fully entered the era of immunotherapy. Immunotherapy‐based treatment has become one of the standard treatments for lung cancer. Immunotherapy has also gradually moved from the back line to the front line, from advanced to early patients. This article focuses on the latest developments in perioperative and advanced lung cancer immunotherapy, discusses the problems and challenges at the current stage, and explores new directions for future development.


menu
Abstract
Full text
Outline
About this article

Advances in medical treatment of breast cancer in 2022

Show Author's information Jingtong Zhai1, Yun Wu1, Fei Ma1 ( ), Virginia Kaklamani2 ( ), Binghe Xu1( )
Department of Medical Oncology, National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
Division of Hematology, Oncology, UT Health San Antonio MD Anderson Cancer Center, San Antonio, Texas, USA

Jingtong Zhai and Yun Wu contributed equally to this work and shared the first authorship.

Abstract

Lung cancer is the malignant tumor with the highest morbidity and mortality in China, and nonsmall cell lung cancer is a common form of lung cancer. After undergoing chemotherapy and molecular targeted therapy, the treatment of lung cancer has now fully entered the era of immunotherapy. Immunotherapy‐based treatment has become one of the standard treatments for lung cancer. Immunotherapy has also gradually moved from the back line to the front line, from advanced to early patients. This article focuses on the latest developments in perioperative and advanced lung cancer immunotherapy, discusses the problems and challenges at the current stage, and explores new directions for future development.

Keywords: nonsmall cell lung cancer, small cell lung cancer, perioperative period, late stage, new immunotherapy

References(79)

1

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3): 209–49. https://doi.org/10.3322/caac.21660
DOI Google Scholar
2

Allemani C, Matsuda T, Di Carlo V, Harewood R, Matz M, Nikšić M, et al. Global surveillance of trends in cancer survival 2000‐14 (Concord‐3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population‐based registries in 71 countries. Lancet. 2018;391(10125): 1023–75. https://doi.org/10.1016/s0140-6736(17)33326-3
DOI Google Scholar
3
Munzone E, Regan M, Cinieri S, Montagna E, Orlando L, Shi R, et al. 216MO a randomized phase Ⅱ trial of metronomic oral vinorelbine plus cyclophosphamide and capecitabine (VEX) vs weekly paclitaxel (P) as first‐or second‐line treatment in patients (pts) with ER+/HER2‐metastatic breast cancer (MBC): the METEORA‐Ⅱ trial (IBCSG 54‐16). Ann Oncol. 2022;33: S636–37. https://www.annalsofoncology.org/article/S0923-7534(22)02106-8/fulltext
DOI
4

Del Mastro L, Poggio F, Blondeaux E, de Placido S, Giuliano M, De Laurentiis M, et al. 134O dose‐dense adjuvant chemotherapy in early‐stage breast cancer patients: end‐of‐study results from a randomised, phase Ⅲ trial of the gruppo italiano mammella (GIM). Ann Oncol. 2022;33:S599–600. https://doi.org/10.1016/j.annonc.2022.07.169
DOI Google Scholar
5
Niu N, Qiu F, Liu T, Guo W, He G, Zhao Y, et al. Primary analysis of MUKDEN 01: a multicenter, single‐arm, prospective, phase 2 study of neoadjuvant treatment with pyrotinib and letrozole plus dalpiciclib in triple‐positive breast cancer. American Society of Clinical Oncology; 2022. https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.588
DOI
6
Loibl S, Jassem J, Sonnenblick A Updated results of Aphinity at 8.4 years median follow up. ESMO Virtual Plenary. 2022. https://oncologypro.esmo.org/meeting-resources/esmo-virtual-plenary-resources/adjuvant-pertuzumab-and-trastuzumab-in-patients-with-early-her-2-positive-breast-cancer-in-aphinity-8.4-years-follow-up#:~:text=analyses%20of%20IDFS.-,Results,0.0060%20required)%20was%20not%20reached.
7
Tarantino P, Tayob N, Dang CT, Yardley D, Isakoff SJ, Valero V, et al. Adjuvant Trastuzumab Emtansine Versus Paclitaxel plus Trastuzumab for Stage I HER2+ Breast Cancer: 5‐year results and correlative analyses from ATEMPT (TBCRC033). SABCS abstract: PD18‐01. 2022. https://clin.larvol.com/abstract-detail/SABCS%202022/61068243
DOI
8

Xu B, Yan M, Ma F, Li W, Ouyang Q, Tong Z, et al. LBA19 pyrotinib or placebo in combination with trastuzumab and docetaxel for HER2‐positive metastatic breast cancer (PHILA): a randomized phase Ⅲ trial. Ann Oncol. 2022;33:S1387. https://doi.org/10.1016/j.annonc.2022.08.014
DOI Google Scholar
9
Krop I, Park YH, Kim S‐B, Borges G, Aksoy S, Gregori JG, et al. Trastuzumab deruxtecan vs physician's choice in patients with HER2+ unresectable and/or metastatic breast cancer previously treated with trastuzumab emtansine: primary results of the randomized phase 3 study DESTINY‐Breast02. 2022. SABCS abstract: GS2‐01. https://clin.larvol.com/abstract-detail/SABCS%202022/60535082
DOI
10
Hurvitz SA, Hegg R, Chung W‐P, Im SA, Jacot W, Ganju V, et al. Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2‐positive metastatic breast cancer: updated results of the randomized, phase 3 study DESTINY‐Breast03. 2022. SABCS abstract: GS2‐02.
DOI
11

Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E, et al. Trastuzumab deruxtecan in previously treated HER2‐low advanced breast cancer. N Engl J Med. 2022;387(1): 9–20. https://doi.org/10.1056/NEJMoa2203690
DOI Google Scholar
12

Modi S, Saura C, Yamashita T, Park YH, Kim SB, Tamura K, et al. Trastuzumab deruxtecan in previously treated HER2‐Positive breast cancer. N Engl J Med. 2020;382(2): 610–21. https://doi.org/10.1056/NEJMoa1914510
DOI Google Scholar
13

Bartsch R, Berghoff AS, Furtner J, Marhold M, Bergen ES, Roider‐Schur S, et al. Trastuzumab deruxtecan in HER2‐positive breast cancer with brain metastases: a single‐arm, phase 2 trial. Nature Med. 2022;28(9): 1840–47. https://doi.org/10.1038/s41591-022-01935-8
DOI Google Scholar
14

Epaillard N, Lusque A, Pistilli B, André F, Bachelot T, Pierga JY, et al. 260P antitumor activity of trastuzumab deruxtecan (T‐DXd) in patients with metastatic breast cancer (mBC) and brain metastases (BMs) from DAISY trial. Ann Oncol. 2022;33:S656. https://doi.org/10.1016/j.annonc.2022.07.299
DOI Google Scholar
15

Lin NU, Borges V, Anders C, Murthy RK, Paplomata E, Hamilton E, et al. Intracranial efficacy and survival with tucatinib plus trastuzumab and capecitabine for previously treated HER2‐Positive breast cancer with brain metastases in the HER2CLIMB trial. J Clin Oncol. 2020;38(23): 2610–19. https://doi.org/10.1200/jco.20.00775
DOI Google Scholar
16

Krop IE, Masuda N, Mukohara T, Takahashi S, Nakayama T, Inoue K, et al. Results from the phase 1/2 study of patritumab deruxtecan, a HER3‐directed antibody‐drug conjugate (ADC), in patients with HER3‐expressing metastatic breast cancer (MBC). J Clin Oncol. 2022;40(16_suppl): 1002–02. https://doi.org/10.1200/JCO.2022.40.16_suppl.1002
DOI Google Scholar
17
Rugo H, Bardia A, Marmé F, Cortes J, Schmid P, Loirat D, et al. LBA76 Overall survival (OS) results from the phase Ⅲ TROPiCS‐02 study of sacituzumab govitecan (SG) vs treatment of physician's choice (TPC) in patients (pts) with HR+/HER2‐metastatic breast cancer (mBC). 2022;33: S1386. https://oncologypro.esmo.org/meeting-resources/esmo-congress/overall-survival-os-results-from-the-phase-iii-tropics-02-study-of-sacituzumab-govitecan-sg-vs-treatment-of-physician-s-choice-tpc-in-patient
DOI
18

Fasching PA, Bardia A, Quiroga V, Park YH, Blancas I, Alonso JL, et al. Neoadjuvant giredestrant (GDC‐9545) plus palbociclib (P) versus anastrozole (A) plus P in postmenopausal women with estrogen receptor–positive, HER2‐negative, untreated early breast cancer (ER+/HER2– eBC): final analysis of the randomized, open‐label, international phase 2 coopERA BC study. J Clin Oncol. 2022;40(16_suppl): 589. https://doi.org/10.1200/JCO.2022.40.16_suppl.589
DOI Google Scholar
19

Gluz O, Nitz UA, Christgen M, Kuemmel S, Braun M, Thill M, et al. LBA14 impact of age, recurrence score (RS) and ovarian function suppression (OFS) on endocrine response to short preoperative endocrine therapy (ET): analysis of ADAPT and ADAPTcycle trials. Ann Oncol. 2022;33:S1382–3. https://doi.org/10.1016/j.annonc.2022.08.008
DOI Google Scholar
20

Tjan‐Heijnen VCG, van Hellemond IEG, Peer PGM, Swinkels ACP, Smorenburg CH, van der Sangen MJC, et al. Extended adjuvant aromatase inhibition after sequential endocrine therapy (DATA): a randomised, phase 3 trial. Lancet Oncol. 2017;18(11): 1502–11. https://doi.org/10.1016/s1470-2045(17)30600-9
DOI Google Scholar
21

Brain E, Viansone AA, Bourbouloux E, Rigal O, Ferrero J‐M, Kirscher S, et al. Final results from a phase Ⅲ randomized clinical trial of adjuvant endocrine therapy ±chemotherapy in women ≥ 70 years old with ER+ HER2‐ breast cancer and a high genomic grade index: the unicancer ASTER 70s trial. J Clin Oncol. 2022;40(16_suppl): 500. https://doi.org/10.1200/JCO.2022.40.16_suppl.500
DOI Google Scholar
22
Pagani O, Partridge A, Niman SM, Ruggeri M, Peccatori FAA. Pregancy outcome and satety of interrupting therapy for women with endocrine responsive breast cancer: primary results from the POSITIVE trial (IBCSG 48‐14/BIG 8‐13). SABCS abstract: GS4‐09. 2022. https://clin.larvol.com/abstract-detail/SABCS%202022/60535183
23

Goetz MP, Plourde P, Stover DG, Bagegni N, Vidal GA, Brufsky A, et al. LBA20 open‐label, randomized study of lasofoxifene (LAS) vs fulvestrant (Fulv) for women with locally advanced/metastatic ER+/HER2‐ breast cancer (mBC), an estrogen receptor 1 (ESR1) mutation, and disease progression on aromatase (AI) and cyclin‐dependent kinase 4/6 (CDK4/6i) inhibitors. Ann Oncol. 2022;33:S1387–8. https://doi.org/10.1016/j.annonc.2022.08.015
DOI Google Scholar
24

Martin Jimenez M, Lim E, Chavez Mac Gregor M, Bardia A, Wu J, Zhang Q, et al. 211MO giredestrant (GDC‐9545) vs physician choice of endocrine monotherapy (PCET) in patients (pts) with ER+, HER2– locally advanced/metastatic breast cancer (LA/mBC): primary analysis of the phase Ⅱ, randomised, open‐label acelERA BC study. Ann Oncol. 2022;33:S633–4. https://doi.org/10.1016/j.annonc.2022.07.250
DOI Google Scholar
25
Bardia A, Bidard FC, Neven P, Streich G, Montero AJ, Forget F, et al. EMERALD phase 3 trial of elacestrant versus standard of care endocrine therapy in patients with ER+/HER2‐ metastatic breast cancer: updated results by duration of prior CDK4/6i in metastatic setting. 2022 SABCS abstract: GS3‐01. https://clin.larvol.com/abstract-detail/SABCS%202022/60535042/279758
DOI
26

Finn RS, Rugo HS, Dieras VC, Harbeck N, Im S‐A, Gelmon KA, et al. Overall survival (OS) with first‐line palbociclib plus letrozole (PAL+LET) versus placebo plus letrozole (PBO+LET) in women with estrogen receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer (ER+/HER2- ABC): analyses from PALOMA‐2. J Clin Oncol. 2022;40(17_suppl): LBA1003. https://doi.org/10.1200/JCO.2022.40.17_suppl.LBA1003
DOI Google Scholar
27

Watanabe K, Niikura N, Kikawa Y, Oba M, Kobayashi K, Tada H, et al. 228P fulvestrant with additional palbociclib in advanced or metastatic hormone receptor‐positive HER2‐negative breast cancer after progression to fulvestrant monotherapy: JBCRG‐M07 (FUTURE trial). Ann Oncol. 2022;33:S642. https://doi.org/10.1016/j.annonc.2022.07.267
DOI Google Scholar
28

Yardley DA, Yap YS, Azim HA, De Boer RH, Campone M, Ring A, et al. 205P pooled exploratory analysis of survival in patients (pts) with HR+/HER2‐ advanced breast cancer (ABC) and visceral metastases (mets) treated with ribociclib (RIB) + endocrine therapy (ET) in the MONALEESA (ML) trials. Ann Oncol. 2022;33:S629. https://doi.org/10.1016/j.annonc.2022.07.239
DOI Google Scholar
29

Kalinsky K, Accordino MK, Chiuzan C, Mundi PS, Trivedi MS, Novik Y, et al. A randomized, phase Ⅱ trial of fulvestrant or exemestane with or without ribociclib after progression on anti‐estrogen therapy plus cyclin‐dependent kinase 4/6 inhibition (CDK 4/6i) in patients (pts) with unresectable or hormone receptor–positive (HR+), HER2‐negative metastatic breast cancer (MBC): MAINTAIN trial. J Clin Oncol. 2022;40(17_suppl): LBA1004. https://doi.org/10.1200/JCO.2022.40.17_suppl.LBA1004
DOI Google Scholar
30

Goetz MP, Toi M, Huober J, Sohn J, Tredan O, Park IH, et al. LBA15 MONARCH 3: interim overall survival (OS) results of abemaciclib plus a nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+, HER2‐ advanced breast cancer (ABC). Ann Oncol. 2022;33:S1384. https://doi.org/10.1016/j.annonc.2022.08.009
DOI Google Scholar
31

André F, Nadal JC, Denys H, Goel S, Litchfield LM, Appiah A, et al. LBA18 final overall survival (OS) for abemaciclib plus trastuzumab +/‐ fulvestrant versus trastuzumab plus chemotherapy in patients with HR+, HER2+ advanced breast cancer (monarcHER): a randomized, open‐label, phase Ⅱ trial. Ann Oncol. 2022;33:S1386–7. https://doi.org/10.1016/j.annonc.2022.08.013
DOI Google Scholar
32

Zhang P, Zhang QY, Hu X, Li W, Tong Z, Sun T, et al. 229P dalpiciclib plus fulvestrant in HR+/HER2- advanced breast cancer (ABC): updated analysis from the phase Ⅲ DAWNA‐1 trial. Ann Oncol. 2022;33:S642–3. https://doi.org/10.1016/j.annonc.2022.07.268
DOI Google Scholar
33

Xu B, Zhang QY, Zhang P, Tong Z, Sun T, Li W, et al. LBA16 dalpiciclib plus letrozole or anastrozole as first‐line treatment for HR+/HER2‐ advanced breast cancer (DAWNA‐2): a phase Ⅲ trial. Ann Oncol. 2022;33:S1384–5. https://doi.org/10.1016/j.annonc.2022.08.010
DOI Google Scholar
34

Jones RH, Casbard AC, Carucci M, Ingarfield‐Herbert K, Butler R, Morgan S, et al. Fulvestrant plus capivasertib versus fulvestrant plus placebo after relapse or progression on an aromatase inhibitor in metastatic, estrogen receptor–positive breast cancer (FAKTION): overall survival and updated progression‐free survival data with enhanced biomarker analysis. J Clin Oncol. 2022;40(16_suppl): 1005. https://doi.org/10.1200/JCO.2022.40.16_suppl.1005
DOI Google Scholar
35
Turner N, Oliveira M, Howell SJ, Dalenc F, Cortés J, Gomez H, et al. Capivasertib and fulvestrant for patients with aromatase inhibitor‐resistant hormone receptor‐positive/human epidermal growth factor receptor 2‐negative advanced breast cancer: results from the Phase Ⅲ CAPItello‐291 trial. SABCS abstract: GS3‐04. 2022. https://clin.larvol.com/abstract-detail/SABCS%202022/60535045/282668
DOI
36

Pusztai L, Denkert C, O'Shaughnessy J, Cortes J, Dent RA, McArthur HL, et al. Event‐free survival by residual cancer burden after neoadjuvant pembrolizumab + chemotherapy versus placebo + chemotherapy for early TNBC: exploratory analysis from KEYNOTE‐522. J Clin Oncol. 2022;40(16_suppl): 503. https://doi.org/10.1200/JCO.2022.40.16_suppl.503
DOI Google Scholar
37

Barrios CH, Saji S, Harbeck N, Zhang H, Jung KH, Patel S, et al. Patient‐reported outcomes from a randomized trial of neoadjuvant atezolizumab‐chemotherapy in early triple‐negative breast cancer. NPJ Breast Cancer. 2022;8(1): 108. https://doi.org/10.1038/s41523-022-00457-3
DOI Google Scholar
38

Sharma P, Stecklein SR, Yoder R, Staley JM, Schwensen K, O'Dea A, et al. Clinical and biomarker results of neoadjuvant phase Ⅱ study of pembrolizumab and carboplatin plus docetaxel in triple‐negative breast cancer (TNBC) (NeoPACT). J Clin Oncol. 2022;40(16_suppl): 513. https://doi.org/10.1200/JCO.2022.40.16_suppl.513
DOI Google Scholar
39

Wang Y, Liu Y, Zhu S, Bi X. 170P phase Ⅱ study of camrelizumab plus chemotherapy as neoadjuvant therapy in patients with early triple‐negative breast cancer. Ann Oncol. 2022;33:S616. https://doi.org/10.1016/j.annonc.2022.07.205
DOI Google Scholar
40

Buisseret L, Loirat D, Aftimos PG, Punie K, Maurer C, Debien V, et al. LBA17 primary endpoint results of SYNERGY, a randomized phase Ⅱ trial, first‐line chemo‐immunotherapy trial of durvalumab, paclitaxel, and carboplatin with or without the anti‐CD73 antibody oleclumab in patients with advanced or metastatic triple‐negative breast cancer (TNBC). Ann Oncol. 2022;33:S1385. https://doi.org/10.1016/j.annonc.2022.08.011
DOI Google Scholar
41

Kyte JA, Andresen NK, Quaghebeur C, Gilje B, Boge B, Gombos A, et al. 215MO ICON—a randomized phase Ⅱb study evaluating chemotherapy combined with ipilimumab and nivolumab in metastatic hormone receptor‐positive breast cancer. Ann Oncol. 2022;33:S636. https://doi.org/10.1016/j.annonc.2022.07.254
DOI Google Scholar
42

Cazzaniga ME, Cordani N, Capici S, Cogliati V, Riva F, Cerrito MG. Metronomic chemotherapy. Cancers. 2021;13(9): 2236. https://doi.org/10.3390/cancers13092236
DOI Google Scholar
43

Seretny M, Currie GL, Sena ES, Ramnarine S, Grant R, MacLeod MR, et al. Incidence, prevalence, and predictors of chemotherapy‐induced peripheral neuropathy: a systematic review and meta‐analysis. Pain. 2014;155(12): 2461–70. https://doi.org/10.1016/j.pain.2014.09.020
DOI Google Scholar
44

Derman BA, Davis AM. Recommendations for prevention and management of chemotherapy‐induced peripheral neuropathy. JAMA. 2021;326(11): 1058–9. https://doi.org/10.1001/jama.2021.7458
DOI Google Scholar
45

Mo H, Yan X, Zhao F, Teng Y, Sun X, Lv Z, et al. Association of taxane type with patient‐reported chemotherapy‐induced peripheral neuropathy among patients with breast cancer. JAMA Netw Open. 2022;5(11): e2239788. https://doi.org/10.1001/jamanetworkopen.2022.39788
DOI Google Scholar
46

Gianni L, Pienkowski T, Im YH, Tseng LM, Liu MC, Lluch A, et al. 5‐year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early‐stage HER2‐positive breast cancer (NeoSphere): a multicentre, open‐label, phase 2 randomised trial. Lancet Oncol. 2016;17(6): 791–800. https://doi.org/10.1016/s1470-2045(16)00163-7
DOI Google Scholar
47

Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, et al. Adjuvant trastuzumab in HER2‐positive breast cancer. N Engl J Med. 2011;365(14): 1273–83. https://doi.org/10.1056/NEJMoa0910383
DOI Google Scholar
48

von Minckwitz G, Procter M, de Azambuja E, Zardavas D, Benyunes M, Viale G, et al. Adjuvant pertuzumab and trastuzumab in early HER2‐Positive breast cancer. N Engl J Med. 2017;377(2): 122–31. https://doi.org/10.1056/NEJMoa1703643
DOI Google Scholar
49

Xu B, Yan M, Ma F, Hu X, Feng J, Ouyang Q, et al. Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2‐positive metastatic breast cancer (PHOEBE): a multicentre, open‐label, randomised, controlled, phase 3 trial. Lancet Oncol. 2021;22(3): 351–60. https://doi.org/10.1016/s1470-2045(20)30702-6
DOI Google Scholar
50

Ogitani Y, Aida T, Hagihara K, Yamaguchi J, Ishii C, Harada N, et al. DS‐8201a, A novel HER2‐Targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T‐DM1. Clin Cancer Res. 2016;22(20): 5097–108. https://doi.org/10.1158/1078-0432.Ccr-15-2822
DOI Google Scholar
51

Modi S, Park H, Murthy RK, Iwata H, Tamura K, Tsurutani J, et al. Antitumor activity and safety of trastuzumab deruxtecan in patients with HER2‐Low‐Expressing advanced breast cancer: results from a phase ib study. J Clin Oncol. 2020;38(17): 1887–96. https://doi.org/10.1200/jco.19.02318
DOI Google Scholar
52

Gradishar WJ, Moran MS, Abraham J, Aft R, Agnese D, Allison KH, et al. Breast cancer, version 3.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2022;20(6): 691–722. https://doi.org/10.6004/jnccn.2022.0030
DOI Google Scholar
53

Bartsch R, Berghoff AS, Furtner J, Marhold M, Bergen ES, Roider‐Schur S, et al. 165MO trastuzumab‐deruxtecan (T‐DXd) in HER2‐positive breast cancer patients (pts) with active brain metastases: primary outcome analysis from the TUXEDO‐1 trial. Ann Oncol. 2022;33:S198. https://doi.org/10.1016/j.annonc.2022.03.184
DOI Google Scholar
54

Yan M, Ouyang Q, Sun T, Niu L, Yang J, Li L, et al. Pyrotinib plus capecitabine for patients with human epidermal growth factor receptor 2‐positive breast cancer and brain metastases (PERMEATE): a multicentre, single‐arm, two‐cohort, phase 2 trial. Lancet Oncol. 2022;23(3): 353–61. https://doi.org/10.1016/s1470-2045(21)00716-6
DOI Google Scholar
55

Freedman RA, Gelman RS, Anders CK, Melisko ME, Parsons HA, Cropp AM, et al. TBCRC 022: a phase Ⅱ trial of neratinib and capecitabine for patients with human epidermal growth factor receptor 2‐positive breast cancer and brain metastases. J Clin Oncol. 2019;37(13): 1081–9. https://doi.org/10.1200/jco.18.01511
DOI Google Scholar
56

Curigliano G, Mueller V, Borges V, Hamilton E, Hurvitz S, Loi S, et al. Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis. Ann Oncol. 2022;33(3): 321–9. https://doi.org/10.1016/j.annonc.2021.12.005
DOI Google Scholar
57

Haikala HM, Jänne PA. Thirty years of HER3: from basic biology to therapeutic interventions. Clin Cancer Res. 2021;27:3528–39. https://doi.org/10.1158/1078-0432.Ccr-20-4465
DOI Google Scholar
58

Da Silva L, Simpson PT, Smart CE, Cocciardi S, Waddell N, Lane A, et al. HER3 and downstream pathways are involved in colonization of brain metastases from breast cancer. Breast Cancer Res. 2010;12(4): R46. https://doi.org/10.1186/bcr2603
DOI Google Scholar
59

Zaman S, Jadid H, Denson AC, Gray JE. Targeting trop‐2 in solid tumors: future prospects. Onco Targets Ther. 2019;12:1781–90. https://doi.org/10.2147/ott.S162447
DOI Google Scholar
60

Syed YY. Sacituzumab govitecan: first approval. Drugs. 2020;80(10): 1019–25. https://doi.org/10.1007/s40265-020-01337-5
DOI Google Scholar
61

Liang J, Zbieg JR, Blake RA, Chang JH, Daly S, DiPasquale AG, et al. GDC‐9545 (Giredestrant): a potent and orally bioavailable selective estrogen receptor antagonist and degrader with an exceptional preclinical profile for ER+ breast cancer. J Med Chem. 2021;64(16): 11841–56. https://doi.org/10.1021/acs.jmedchem.1c00847
DOI Google Scholar
62

Hurvitz SA, Park YH, Bardia A, Quiroga V, López‐Valverde V, Steinseifer J, et al. LBA14 neoadjuvant giredestrant (GDC‐9545) + palbociclib (palbo) vs anastrozole (A) + palbo in post‐menopausal women with oestrogen receptor‐positive, HER2‐negative, untreated early breast cancer (ER+/HER2– eBC): interim analysis of the randomised, open‐label, phase Ⅱ coopERA BC study. Ann Oncol. 2021;32:S1285–6. https://doi.org/10.1016/j.annonc.2021.08.2086
DOI Google Scholar
63

Bardia A, Fernando TM, Fasching PA, Quiroga Garcia V, Park YH, Giltnane JM, et al. 144P neoadjuvant giredestrant (GDC‐9545) + palbociclib (P) vs anastrozole (A) + P in postmenopausal women with oestrogen receptor‐positive, HER2‐negative, untreated early breast cancer (ER+/HER2– eBC): biomarker subgroup analysis of the randomised, phase Ⅱ coopERA BC study. Ann Oncol. 2022;33:S605–6. https://doi.org/10.1016/j.annonc.2022.07.179
DOI Google Scholar
64

Baek SY, Noh WC, Ahn S‐H, Kim H‐A, Ryu JM, Kim SI, et al. Adding ovarian function suppression to tamoxifen in young women with hormone‐sensitive breast cancer who remain premenopausal or resume menstruation after chemotherapy: 8‐year follow‐up of the randomized ASTRRA trial. J Clin Oncol. 2022;40(16_suppl): 506. https://doi.org/10.1200/JCO.2022.40.16_suppl.506
DOI Google Scholar
65

Tjan‐Heijnen VCG, Lammers SWM, Geurts SME, Vriens IJH, Swinkels ACP, Smorenburg CH, et al. 133O extended adjuvant aromatase inhibition after sequential endocrine therapy: final results of the phase Ⅲ DATA trial. Ann Oncol. 2022;33:S599. https://doi.org/10.1016/j.annonc.2022.07.168
DOI Google Scholar
66

Jhaveri KL, Boni V, Sohn J, Villanueva‐Vásquez R, Bardia A, Schmid P, et al. Safety and activity of single‐agent giredestrant (GDC‐9545) from a phase ia/b study in patients (pts) with estrogen receptor‐positive (ER+), HER2‐negative locally advanced/metastatic breast cancer (LA/mBC). J Clin Oncol. 2021:39(15_suppl): 1017. https://doi.org/10.1200/JCO.2021.39.15_suppl.1017
DOI Google Scholar
67

Bidard FC, Kaklamani VG, Neven P, Streich G, Montero AJ, Forget F, et al. Elacestrant (oral selective estrogen receptor degrader) versus standard endocrine therapy for estrogen receptor‐positive, human epidermal growth factor receptor 2‐negative advanced breast cancer: results from the randomized phase Ⅲ EMERALD trial. J Clin Oncol. 2022;40(28): 3246–56. https://doi.org/10.1200/jco.22.00338
DOI Google Scholar
68

Tanguy ML, Cabel L, Berger F, Pierga JY, Savignoni A, Bidard FC. Cdk4/6 inhibitors and overall survival: power of first‐line trials in metastatic breast cancer. NPJ Breast Cancer. 2018;4:14. https://doi.org/10.1038/s41523-018-0068-4
DOI Google Scholar
69

Finn RS, Martin M, Rugo HS, Jones S, Im SA, Gelmon K, et al. Palbociclib and letrozole in advanced breast cancer. N Engl J Med. 2016;375(20): 1925–36. https://doi.org/10.1056/NEJMoa1607303
DOI Google Scholar
70

Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch‐Shimon S, et al. Updated results from MONALEESA‐2, a phase Ⅲ trial of first‐line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor‐positive, HER2‐negative advanced breast cancer. Ann Oncol. 2018;29(7): 1541–7. https://doi.org/10.1093/annonc/mdy155
DOI Google Scholar
71

Slamon DJ, Neven P, Chia S, Jerusalem G, De Laurentiis M, Im S, et al. Ribociclib plus fulvestrant for postmenopausal women with hormone receptor‐positive, human epidermal growth factor receptor 2‐negative advanced breast cancer in the phase Ⅲ randomized MONALEESA‐3 trial: updated overall survival. Ann Oncol. 2021;32:1015–24. https://doi.org/10.1016/j.annonc.2021.05.353
DOI Google Scholar
72

Tripathy D, Im SA, Colleoni M, Franke F, Bardia A, Harbeck N, et al. Ribociclib plus endocrine therapy for premenopausal women with hormone‐receptor‐positive, advanced breast cancer (MONALEESA‐7): a randomised phase 3 trial. Lancet Oncol. 2018;19(7): 904–15. https://doi.org/10.1016/s1470-2045(18)30292-4
DOI Google Scholar
73

Tolaney SM, Wardley AM, Zambelli S, Hilton JF, Troso‐Sandoval TA, Ricci F, et al. Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard‐of‐care chemotherapy in women with hormone receptor‐positive, HER2‐positive advanced breast cancer (monarcHER): a randomised, open‐label, phase 2 trial. Lancet Oncol. 2020;21(6): 763–75. https://doi.org/10.1016/s1470-2045(20)30112-1
DOI Google Scholar
74

Xu B, Zhang Q, Zhang P, Hu X, Li W, Tong Z, et al. Dalpiciclib or placebo plus fulvestrant in hormone receptor‐positive and HER2‐negative advanced breast cancer: a randomized, phase 3 trial. Nature Med. 2021;27(11): 1904–9. https://doi.org/10.1038/s41591-021-01562-9
DOI Google Scholar
75

O'Shaughnessy J, Thaddeus Beck J, Royce M. Everolimus‐based combination therapies for HR+, HER2‐ metastatic breast cancer. Cancer Treat Rev. 2018;69:204–14. https://doi.org/10.1016/j.ctrv.2018.07.013
DOI Google Scholar
76

Jones RH, Casbard A, Carucci M, Cox C, Butler R, Alchami F, et al. Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor‐positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial. Lancet Oncol. 2020;21(3): 345–57. https://doi.org/10.1016/s1470-2045(19)30817-4
DOI Google Scholar
77

Schmid P, Cortes J, Dent R, Pusztai L, McArthur H, Kümmel S, et al. Event‐free survival with pembrolizumab in early triple‐negative breast cancer. N Engl J Med. 2022;386(6): 556–67. https://doi.org/10.1056/NEJMoa2112651
DOI Google Scholar
78

Mittendorf EA, Zhang H, Barrios CH, Saji S, Jung KH, Hegg R, et al. Neoadjuvant atezolizumab in combination with sequential nab‐paclitaxel and anthracycline‐based chemotherapy versus placebo and chemotherapy in patients with early‐stage triple‐negative breast cancer (IMpassion031): a randomised, double‐blind, phase 3 trial. Lancet. 2020;396(10257): 1090–100. https://doi.org/10.1016/s0140-6736(20)31953-x
DOI Google Scholar
79

Liu J, Wang Y, Tian Z, Lin Y, Li H, Zhu Z, et al. Multicenter phase Ⅱ trial of camrelizumab combined with apatinib and eribulin in heavily pretreated patients with advanced triple‐negative breast cancer. Nat Commun. 2022;13(1): 3011. https://doi.org/10.1038/s41467-022-30569-0
DOI Google Scholar
Publication history
Copyright
Acknowledgements
Rights and permissions

Publication history

Received: 16 November 2022
Accepted: 18 December 2022
Published: 21 February 2023
Issue date: February 2023

Copyright

© 2023 The Authors. Cancer Innovation published by John Wiley & Sons Ltd. on behalf of Tsinghua University Press.

Acknowledgements

ACKNOWLEDGMENTS

None.

Rights and permissions

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

Return